D. Payne

发表

Nat. Rev. Drug Disc.

D. Pompliano, D. Payne, M. Gwynn, 2007 .

Drugs for bad bugs: confronting the challenges of antibacterial discovery

D. Pompliano, D. Payne, M. Gwynn, 2007, Nature Reviews Drug Discovery.

Challenges of antibacterial discovery revisited

David J Payne, Michael N Gwynn, D. Payne, 2010, Annals of the New York Academy of Sciences.

Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases

D. Payne, D. Knowles, D. Winstanley, 1994, Antimicrobial Agents and Chemotherapy.

TEM-E1: a novel β-lactamase conferring resistance to ceftazidime

S. Amyes, D. Payne, M. Marriott, 1989 .

Separation of plasmid-mediated extended spectrum beta-lactamases by fast protein liquid chromatography (FPLC system).

S. Amyes, D. Payne, M. Marriott, 1990, FEMS microbiology letters.

Transferable cephalosporin resistance not inhibited by clavulanate in Escherichia coli

B. Cookson, N. Woodford, S. Amyes, 1990, The Lancet.

Nucleotide and Amino Acid Sequences of the Metallo-β-Lactamase, ImiS, from Aeromonas veronii bv. sobria

A. MacGowan, P. Bennett, D. Payne, 1998, Antimicrobial Agents and Chemotherapy.

Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents

Martha S. Head, Xiayang Qiu, Cheryl A. Janson, 2002, Antimicrobial Agents and Chemotherapy.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Xiayang Qiu, David J Payne, M. Head, 2003, Journal of medicinal chemistry.

Characterization of Streptococcus pneumoniae 5-enolpyruvylshikimate 3-phosphate synthase and its activation by univalent cations.

N. Wallis, M. Mazzulla, D. Payne, 2000, European journal of biochemistry.

Technologies to address antimicrobial resistance

R. Rappuoli, E. De Gregorio, D. Payne, 2018, Proceedings of the National Academy of Sciences.

Bacterial resistance mechanisms as therapeutic targets.

I. Chopra, D. Payne, K. Coleman, 1994, The Journal of antimicrobial chemotherapy.

Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.

A. D. Russell, S. Hiom, D. Payne, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

beta-Lactamase ragged ends detected by electrospray mass spectrometry correlates poorly with multiple banding on isoelectric focusing.

C. Robinson, D. Payne, R. Aplin, 1994, Biological mass spectrometry.

Cloning and sequence analysis of blaBIL-1, a plasmid-mediated class C beta-lactamase gene in Escherichia coli BS

A. Fosberry, D. Payne, J. E. Hodgson, 1994, Antimicrobial Agents and Chemotherapy.

Rapid identification of metallo- and serine beta-lactamases

D. Payne, J. Neale, D. Knowles, 1994, Antimicrobial Agents and Chemotherapy.

Rapid Identification of Metallo- and Serine 3-Lactamases

D. Payne, J. Neale, R. Cramp, 2022 .

Delivering novel targets and antibiotics from genomics.

M. Rosenberg, D. Payne, D. Holmes, 2001, Current opinion in investigational drugs.

The impact of genomics on novel antibacterial targets.

N. Wallis, M. Rosenberg, D. Payne, 2000, Current opinion in drug discovery & development.

Desperately Seeking New Antibiotics

D. Payne, 2008, Science.

Stability of cefdinir (C1-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases.

S. Amyes, D. Payne, 1993, Journal of medical microbiology.

The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.

S. Amyes, D. Payne, 1992, Drugs under experimental and clinical research.

Characterisation of a unique ceftazidime-hydrolysing beta-lactamase, TEM-E2.

S. Amyes, D. Payne, M. Marriott, 1990, Journal of medical microbiology.

Characterisation of a unique ceftazidime-hydrolysing p-lactamase , TEME 2

D. Payne, S. G. B. AMYESt, 2022 .

Separation of plasmid-mediated extended spectrum β-lactamases by fast protein liquid chromatography (FPLC system)

S. Amyes, D. Payne, M. Marriott, 1990 .

Inhibition of metallo-beta-lactamases by a series of thiol ester derivatives of mercaptophenylacetic acid.

D. Payne, B. Gasson, J. Bateson, 1997, FEMS microbiology letters.

A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible beta-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity.

A. MacGowan, P. Bennett, D. Payne, 1995, The Journal of antimicrobial chemotherapy.

Transferable resistance to extended-spectrum beta-lactams: a major threat or a minor inconvenience?

S. Amyes, D. Payne, 1991, The Journal of antimicrobial chemotherapy.

Selection of Retapamulin, a Novel Pleuromutilin for Topical Use

D. Payne, J. West, S. Rittenhouse, 2006, Antimicrobial Agents and Chemotherapy.

Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.

J. Frère, M. Galleni, S. Abdel-Meguid, 2000, Biochemistry.

β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments

D. Payne, L. Miller, K. Ratnam, 2001 .

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

C. Janson, A. Fosberry, D. D. Jaworski, 2001, Bioorganic & medicinal chemistry letters.

Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases

Cheryl A. Janson, C. Janson, D. Tew, 2002, Antimicrobial Agents and Chemotherapy.

Molecular basis for triclosan activity involves a flipping loop in the active site

S. Abdel-Meguid, C. Janson, D. Payne, 2008, Protein science : a publication of the Protein Society.

Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus

M. Head, N. Wallis, D. Payne, 2002, Antimicrobial Agents and Chemotherapy.

1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

C. Janson, A. Fosberry, D. Heerding, 2001, Bioorganic & medicinal chemistry letters.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Xiayang Qiu, David J Payne, M. Head, 2002, Journal of medicinal chemistry.

The synthesis and serine β-lactamase inhibitory activity of some phosphonamidate analogues of dipeptides

D. Payne, J. Neale, D. Tolson, 1994 .

Isolation and structure determination of two novel phenazines from a Streptomyces with inhibitory activity against metallo-enzymes, including metallo-β-lactamase

M. Gilpin, D. Payne, M. Fulston, 1995 .

beta-lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors

D. Payne, D J Payne, J H Bateson, 2000, Expert opinion on investigational drugs.

Inhibition of metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives

D. Payne, A C Marshall, D J Payne, 1997, Antimicrobial agents and chemotherapy.

Metallo-beta-lactamases--a new therapeutic challenge.

D. Payne, D J Payne, 1993, Journal of medical microbiology.

Molecular Approaches for the Detection and Identification of β-Lactamases.

D. Payne, C. Thomson, 1998, Methods in molecular medicine.

Identification of antimicrobial targets using a comprehensive genomic approach.

M. Etherton, Yinduo Ji, M. Rosenberg, 2004, Pharmacogenomics.

The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents.

A. Tomasz, D. Payne, 2004, Current opinion in microbiology.

Two Active Forms of UDP-N-Acetylglucosamine Enolpyruvyl Transferase in Gram-Positive Bacteria

James R. Brown, N. Wallis, D. Payne, 2000, Journal of bacteriology.

A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan.

C. J. Thomson, S. Amyes, D. Payne, 1998, The Journal of antimicrobial chemotherapy.

Finding the gems using genomic discovery: antibacterial drug discovery strategies – the successes and the challenges

D. Payne, D. Holmes, P. Chan, 2004 .

Genomic approaches to antibacterial discovery.

David J Payne, Michael N Gwynn, David J Holmes, 2004, Methods in molecular biology.

Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).

R. Heath, C. Rock, N. Wallis, 2003, The Biochemical journal.

Production of metal dependent beta-lactamases by clinical strains of Bacteroides fragilis isolated before 1987.

A. Fosberry, D. Payne, C. Reading, 1996, The Journal of antimicrobial chemotherapy.

Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

D. Payne, L. Miller, K. Ratnam, 2001, Current opinion in pharmacology.

A conserved residue at the extreme C-terminus of FtsZ is critical for the FtsA-FtsZ interaction in Staphylococcus aureus.

K. Pearce, D. Payne, K. Yan, 2000, Biochemical and biophysical research communications.

Kinetic and physical studies of beta-lactamase inhibition by a novel penem, BRL 42715.

J. W. Page, D. Payne, D. Knowles, 1994, The Biochemical journal.

Time for a change: addressing R&D and commercialization challenges for antibacterials

David Findlay, D. Findlay, D. Payne, 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus.

D. D. Jaworski, G. V. Van Aller, D. Payne, 2001, The Journal of antimicrobial chemotherapy.

Antibacterial Drug Discovery in the Age of Resistance: New technologies and partnerships are helping to meet the challenges of antibacterial R&D

D. Payne, Andrew B. Benowitz, J. Hoover, 2010 .

Characterization of the plasmid mediated beta-lactamase BIL-1.

N. Woodford, S. Amyes, D. Payne, 1992, The Journal of antimicrobial chemotherapy.

Characterization of the plasmid mediated β-lactamase BIL-1

N. Woodford, D. Payne, S. Amyes, 1992 .

Biochemical and Enzyme Kinetic Applications for the Characterization of βLactamases.

D. Payne, T. Farmer, 1998, Methods in molecular medicine.

TEM‐E4: A β‐LACTAMASE WHICH CONFERS TRANSFERABLE RESISTANCE TO CEFTAZIDIME

C. Christodoulou, D. Payne, S. Amyes, 1990 .

The effects of βbT-lactams on the isoelectric focusing of βbT-lactamases

S. Amyes, D. Payne, 1994 .

The Kinetic Mechanism of 5-Enolpyruvylshikimate-3-Phosphate Synthase from a Gram-Positive Pathogen Streptococcus Pneumoniae

N. Wallis, D. Payne, Wensheng Du, 2000, Journal of enzyme inhibition.

Reaction: Alternative Modalities to Address Antibiotic-Resistant Pathogens

F. Bagnoli, D. Payne, 2017 .

Towards new business models for R&D for novel antibiotics.

J Weigelt, R. Peeling, B. Munos, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

The incidence of antibiotic resistance in aerobic faecal flora in south India.

C. J. Thomson, M. Jesudason, U. Mukundan, 1992, The Journal of antimicrobial chemotherapy.

Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme.

B. Sutton, D. Payne, S. Fabiane, 1998, Biochemistry.

No let up in the search for novel antibiotics

Z. Hong, D. Payne, A. Portnoy, 2009, Expert review of anti-infective therapy.

Novel antibacterials: a genomics approach to drug discovery.

Ricardo Macarron, David J Payne, Pan F Chan, 2002, Current drug targets. Infectious disorders.

Use of the Surgical Wound Infection Model To Determine the Efficacious Dosing Regimen of Retapamulin, a Novel Topical Antibiotic

D. Payne, S. Rittenhouse, J. Hoover, 2006, Antimicrobial Agents and Chemotherapy.

Dictionary of antibiotics and related substances : with CD-ROM

D. Payne, B. Bycroft, 2013 .

The production of a novel carbapenem-hydrolysing beta-lactamase in Aeromonas veronii biovar sobria, and its association with imipenem resistance.

C. J. Thomson, S. Amyes, D. Payne, 1998, The Journal of antimicrobial chemotherapy.

Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus.

Yinduo Ji, M. Rosenberg, D. Payne, 2004, FEMS microbiology letters.

Penetration of β-lactamase inhibitors into the periplasm of Gram-negative bacteria

D. Payne, B. Degnan, T. Farmer, 1999 .

Phosphonamidate analogues of dipeptides with carboxypeptidase A and beta-lactamase-inhibitory activity: elucidation of the mechanism of beta-lactamase inhibition by electrospray mass spectrometry.

J. Frère, D. Payne, P. Ledent, 1996, The Biochemical journal.

Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery.

P. Warren, D. Payne, D. Holmes, 2001, Drug discovery today.

Sensitivity of L-2 type β-lactamases from Stenotrophomonas maltophilia to serine active site β-lactamase inhibitors

D. Payne, P. Rowling, I. Simpson, 1996 .

Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors.

D. Payne, P. Rowling, I. Simpson, 1996, Journal of Antimicrobial Chemotherapy.

Novel antibacterial strategies, with emphasis on the characterization of β-lactamases and β-lactamase inhibitors

D. Payne, 2002 .

Mutants of the TEM-1 β-lactamase conferring resistance to ceftazidime

S. Amyes, D. Payne, M. Marriott, 1989 .

Regions of FtsZ important for self-interaction in Staphylococcus aureus.

D. Payne, T. Sossong, K. Yan, 2001, Biochemical and biophysical research communications.

Novel targets for the future development of antibacterial agents

M. Rosenberg, D. Payne, D. Holmes, 2002, Symposium series.

Alternatives to antibiotics-a pipeline portfolio review.

I. Henderson, R. Hancock, Christopher M Thomas, 2016, The Lancet. Infectious diseases.

The Synthesis and Serine β‐Lactamase Inhibitory Activity of Some Phosphonamidate Analogues of Dipeptides.

D. Payne, J. Neale, D. Tolson, 1995 .

Alternatives to antibiotics-a pipeline portfolio review.

Martha R. J. Clokie, I. Henderson, R. Hancock, 2016, The Lancet. Infectious diseases.

Faculty Opinions recommendation of Clinical decisions. Management of skin and soft-tissue infection--polling results.

D. Payne, 2008 .